Medicare Enrolled
Dr. Rishi Sawhney, M.D.
Internal Medicine · Pleasanton, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Sawhney from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sawhney?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sawhney
Dr. Rishi Sawhney is an internal medicine specialist in Pleasanton, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Sawhney performed 38,658 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Sawhney received a total of $223,772 from 27 pharmaceutical and/or device companies across 249 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sawhney is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 1% volume in CA
$223,772 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗38,658
Medicare services
Top 1% in CA for internal medicine
Not available
Unique patients (not deduplicated)
$18
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
12,750 | $1 | $5 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
7,700 | $2 | $12 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
4,500 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 3,780 | $19 | $81 |
| Pembrolizumab injection (Keytruda) | 3,000 | $43 | $195 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,633 | $109 | $432 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
970 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 740 | $1 | $5 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
689 | $161 | $523 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
564 | $87 | $468 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
424 | $8 | $33 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
258 | $16 | $119 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
188 | $13 | $104 |
| New patient office visit, complex (60-74 min) | 157 | $194 | $772 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
137 | $7 | $30 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
129 | $2 | $10 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
119 | $138 | $1,049 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
104 | $105 | $365 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
83 | $93 | $390 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
83 | $1 | $3 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
69 | $29 | $222 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
64 | $64 | $377 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 63 | $134 | $593 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
58 | $24 | $173 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
55 | $74 | $320 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
54 | $67 | $382 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
54 | $142 | $671 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
48 | $70 | $264 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
45 | $19 | $92 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
41 | $35 | $274 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
33 | $30 | $170 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
26 | $13 | $78 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
25 | $38 | $298 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
15 | $154 | $739 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
33.7% high complexity
57.5% medium
8.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$223,772
Total received (2018-2024)
Avg $31,967/year across 7 years
Top 1% in CA for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
27
Companies
249
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$18,664
2023
$9,398
2022
$10,754
2021
$20,672
2020
$37,400
2019
$56,468
2018
$70,416
Payments by company (2024)
Rigel Pharmaceuticals, Inc.
$15,547
Olympus America Inc.
$1,639
Takeda Pharmaceuticals U.S.A., Inc.
$1,302
Merck Sharp & Dohme LLC
$59
SpringWorks Therapeutics, Inc.
$47
E.R. Squibb & Sons, L.L.C.
$26
PFIZER INC.
$25
Gilead Sciences, Inc.
$19
Top 3 companies account for 99.1% of 2024 payments
All-time payments by company (2018-2024) ›
Rigel Pharmaceuticals, Inc.
$90,442
Merck Sharp & Dohme Corporation
$63,479
Takeda Pharmaceuticals U.S.A., Inc.
$39,632
Janssen Pharmaceuticals, Inc
$16,051
E.R. Squibb & Sons, L.L.C.
$5,733
AMAG Pharmaceuticals, Inc.
$4,951
Olympus America Inc.
$1,639
PFIZER INC.
$464
Abbott Laboratories
$459
Ethicon Inc.
$159
IntrinsiQ Specialty Solutions, Inc.
$100
ABBVIE INC.
$100
Daiichi Sankyo Inc.
$68
Pharmacyclics LLC, An AbbVie Company
$61
Merck Sharp & Dohme LLC
$59
Amgen Inc.
$51
SpringWorks Therapeutics, Inc.
$47
Gilead Sciences, Inc.
$43
Coherus Biosciences Inc.
$41
GlaxoSmithKline, LLC.
$35
Acrotech Biopharma LLC
$26
Seattle Genetics, Inc.
$25
Pharmacyclics LLC, an AbbVie Company
$23
Stemline Therapeutics Inc.
$23
Celgene Corporation
$23
SOBI, INC
$20
Novartis Pharmaceuticals Corporation
$17
Top 3 companies account for 86.5% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · BELEODAQ · BLENREP · BRAFTOVI · Doptelet · EVENITY · EVIS EXERA III COLONOVIDEOSCOPE · Enhertu · FERAHEME · FRUZAQLA · IBRANCE · ICLUSIG · IMBRUVICA · INJECTAFER · INLYTA · KEYTRUDA · LORBRENA · MEKINIST · N/A · NINLARO · Nplate · OGSIVEO · OPDIVO · Orserdu · Pomalyst · Rezlidhia · SUTENT · Tavalisse · Udenyca · VELCADE · VENCLEXTA · XARELTO
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Internal medicine physicians in nearby ZIP areas
1,648
County median income
$126,240
Nearest hospital to ZIP centroid (approximate)
STANFORD HEALTH CARE TRI-VALLEY
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Sawhney is a mixed practice specialist, with above-average Medicare volume (top 1% in CA), with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Sawhney experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Sawhney performed 12,750 iron infusion (injectafer) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Sawhney receive payments from pharmaceutical companies?
Yes. Dr. Sawhney received a total of $223,772 from 27 companies across 249 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sawhney's costs compare to other internal medicine physicians in Pleasanton?
Dr. Sawhney's average Medicare payment per service is $18. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sawhney) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Pleasanton
Browse internal medicine physicians in Pleasanton ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in CA
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in CA
Which CA internal medicine physicians receive the most from drug and device companies.
By company
Rigel Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Rigel Pharmaceuticals, Inc.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology